Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 10/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.41 |
| ▸ | PDE4A | P27815 | 9/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060307 | 0.98 | PDE4B (0.42) | PDE4DPDE4BPDE4APDE4CPOLB | |
| SCHEMBL7711770 | 0.74 | PDE4D (0.47) | PDE4DPDE4BPDE4APDE4CP2RX7 | |
| SCHEMBL29953447 | 0.73 | POLB (0.34) | POLB | |
| SCHEMBL4981553 | 0.72 | ERN1 (0.40) | PDE4D | |
| SCHEMBL16068427 | 0.71 | CNR2 (0.33) | PDE4DPDE4BPDE4APDE4CP2RX7 | |
| SCHEMBL15305386 | 0.71 | PDE4B (0.42) | PDE4DPDE4BPDE4APDE4CCSNK2A1 | |
| SCHEMBL320672 | 0.70 | ALDH1A1 (0.52) | — | |
| SCHEMBL29957556 | 0.70 | POLB (0.35) | POLBCSNK2A1 | |
| SCHEMBL29955833 | 0.70 | POLB (0.35) | POLB | |
| SCHEMBL29958343 | 0.70 | ERN1 (0.35) | POLBKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2011141756-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | LRRK2, PARK7, GRK3 | PDE4D 2010/4885PDE4B 1764/4885PDE4A 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.